-
PDF
- Split View
-
Views
-
Cite
Cite
Christopher Bennett, Sarah Kohe, Florence Burte, Heather Rose, Debbie Hicks, Ed Schwalbe, Stephen Crosier, Lisa Storer, Anbarasu Lourdusamy, Martin Wilson, Shivaram Avula, Dipayan Mitra, Robert Dineen, Simon Bailey, Daniel Williamson, Richard Grundy, Steven Clifford, Andrew Peet, MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES, Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii410, https://doi.org/10.1093/neuonc/noaa222.573
- Share Icon Share
Abstract
SHH medulloblastoma patients have a variable prognosis. Infants (<3–5 years at diagnosis) are associated with a good prognosis, while disease-course in childhood is associated with specific prognostic biomarkers (MYCN amplification, TP53 mutation, LCA histology; all high-risk). There is an unmet need to identify prognostic subgroups of SHH tumours rapidly in the clinical setting, to aid in real-time risk stratification and disease management. Metabolite profiling is a powerful technique for characterising tumours. High resolution magic angle spinning NMR spectroscopy (HR-MAS) can be performed on frozen tissue samples and provides high quality metabolite information. We therefore assessed whether metabolite profiles could identify subsets of SHH tumours with prognostic potential. Metabolite concentrations of 22 SHH tumours were acquired by HR-MAS and analysed using unsupervised hierarchical clustering. Methylation profiling assigned the infant and childhood SHH subtypes, and clinical and molecular features were compared between clusters. Two clusters were observed. A significantly higher concentration of lipids was observed in Cluster 1 (t-test, p=0.012). Cluster 1 consisted entirely of childhood-SHH whilst Cluster 2 included both childhood-SHH and infant-SHH subtypes. Cluster 1 was enriched for high-risk markers - LCA histology (3/7 v. 0/5), MYCN amplification (2/7 v. 0/5), TP53 mutations (3/7 v. 1/5) and metastatic disease - whilst having a lower proportion of TERT mutations (0/7 v. 2/5) than Cluster 2. These pilot results suggest that (i) it is possible to identify childhood-SHH patients linked to high-risk clinical and molecular biomarkers using metabolite profiles and (ii) these may be detected non-invasively in vivo using magnetic-resonance spectroscopy.
- nuclear magnetic resonance
- mutation
- biological markers
- child
- disease progression
- tp53 gene
- infant
- medulloblastoma
- methylation
- neoplasm metastasis
- protein p53
- signs and symptoms
- spectrum analysis
- vertigo
- diagnosis
- disease management
- histology
- lipids
- neoplasms
- patient prognosis
- childhood cancer
- prognostic marker
- stratification
- metabolites
- amplification
- mycn gene
- tissue specimen